home.aspx
 
. https://biotechnology.report/Resources/Whitepapers/c5079c89-4b98-477b-840e-3e44b7fc987b_Real-world-evidence-Driving-a-new-drug-development-paradigm-in-oncology.pdf
whitepaper
SHARESHARESHARE
REAL-WORLD EVIDENCE: DRIVING A NEW DRUG DEVELOPMENT PARADIGM IN ONCOLOGY
Evidence generation in oncology is at a key inflection point. Given the rapid pace of scientific innovation, historical approaches to drug development are increasingly burdensome, with randomized controlled trials remaining incredibly costly and time intensive to conduct, and having a low certainty of success. Biopharmaceutical companies will collectively invest USD 50 billion to support oncology research and development in 2018, with a ~3 percent probability of success for any individual product from preclinical through registration phases.1 Despite this investment, many completed trials fail to answer critical questions for payors and healthcare providers, exacerbating the wide evidence gap that already exists between clinical research and practice. DOWNLOAD